Quarterly report pursuant to Section 13 or 15(d)

Sale of ENTADFI Assets (Narrative) (Details)

v3.24.1
Sale of ENTADFI Assets (Narrative) (Details) - USD ($)
3 Months Ended 12 Months Ended
Oct. 03, 2023
Sep. 29, 2023
Apr. 19, 2023
Dec. 31, 2023
Sep. 30, 2023
Sep. 30, 2024
Apr. 30, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gain on asset disposal       $ 918,372      
ENTADFI [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Purchase price     $ 20,000,000.0        
Proceeds from sale of assets   $ 1,000,000.0 6,000,000.0        
Consideration receivable     $ 4,000,000.0        
Gain on asset disposal $ 900,000       $ 5,700,000    
ENTADFI [Member] | Blue Water Vaccines, Inc [Member] | Preferred Stock [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of shares issued in transaction 3,000            
Value assigned to shares issued in transaction $ 900,000            
Redemption waiting period 1 year            
Preferred stock, stated value $ 1,000            
Preferred stock, redemption price $ 0.5254            
ENTADFI [Member] | Blue Water Vaccines, Inc [Member] | Common Stock [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Common shares issuable upon conversion of preferred stock 5,709,935            
Scenario, Forecast [Member] | ENTADFI [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Consideration receivable           $ 5,000,000.0 $ 5,000,000.0
Contingent consideration           $ 80,000,000.0